Drug intelligence / Profile preview

Sekkei Bio thermostable insulin

Development stage: Preclinical
Lead developer: Sekkei Bio
Modality: Peptides
Administration: Subcutaneous

Overview

Sekkei Bio is developing a thermostable insulin formulation for the treatment of diabetes. The program leverages the company's proprietary Sq-PROT computational platform to design insulin peptides with enhanced structural stability, aiming to eliminate the requirement for cold-chain storage and transport. By targeting the insulin receptor, this biologic candidate functions as an insulin replacement therapy intended to improve the affordability and accessibility of diabetes care, particularly in regions with limited refrigeration infrastructure.

Other names: thermostable insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Sekkei Bio thermostable insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sekkei Bio thermostable insulin.

Explore the full profile